OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Charity Registration No. 1146902

SHINE CANCER SUPPORT

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 DECEMBER 2025

Waverley House 115-119 Holdenhurst Road Bournemouth Dorset BH8 8DY

SHINE CANCER SUPPORT

CONTENTS

Page
Charity information 1
Trustees' report 2 - 12
Independent examiner's report 13
Statement of financial activities 14
Statement of financial position 15
Statement of cash flows 16
Notes to the financial statements 17 - 30

SHINE CANCER SUPPORT

CHARITY INFORMATION

Trustees C Riley R J Cranefield R Salter L Purandare J Talman F A Woodcock Charity number 1146902 Independent examiner TC Group Waverley House 115-119 Holdenhurst Road Bournemouth Dorset BH8 8DY

SHINE CANCER SUPPORT

TRUSTEES' REPORT

FOR THE PERIOD ENDED 31 DECEMBER 2025

The trustees present their annual report and financial statements for the period ended 31 December 2025.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

The period covered by these financial statements is 1 October 2024 to 31 December 2025. This totals 15 months and is to allow us to adjust our future reporting dates to align with the calendar year. This will make activity reporting and grant reconciliation more clear for future years. For this period, comparatives will not be entirely compatible due to the additional 3 months included in the reports. We have the authority to make this change following guidance from the Charity Commission.

Objectives and activities

To summarise the purposes of Shine Cancer Support as set out in our governing document, our ‘Charitable Objects’ are:

  1. To promote physical and mental health by providing a support network for adults and their families who have been diagnosed with or in the past have suffered from cancer, through the provision of services including information, open meetings, social events, and a website.

  2. To advance the education of the public in the subject of cancer and other cancer related subjects such as but not limited to cancer prevention and cancer diagnoses.

The board of Trustees have been provided with guidance issued by the Charity Commission on public benefit. This report summarises the main activities in relation to those purposes above for the public benefit, summarises the primary achievements of Shine Cancer Support, and demonstrates the difference that our work has made to its beneficiaries and the wider public between 1 October 2024 and 31 December 2025.

Public benefit

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

SHINE CANCER SUPPORT

TRUSTEES' REPORT (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

Every aspect of life can be affected by a cancer diagnosis, including work, fertility, finances, insurance, sex, dating, and mental health. Younger adults often face these challenges while managing careers, caring responsibilities, relationships, and plans for the future, yet most cancer support remains designed with older people in mind, or stops at age 24. This means that an increasing cohort of adults in their 20s, 30s and 40s are not getting the support or information they need to live well after a life-changing diagnosis.

At the same time, more and more research in the last two years has shown that rates of ‘early onset cancer’ (cancer in those under 50) is increasing. This means that there are increasing numbers of younger adults who need tailored support but struggle to find it (see for example, Ledford 2024; Bray 2024; and Shelton et al 2024). Many tell us that they are the youngest person in the waiting room, or that friends and colleagues ‘don’t get it’, compounding feelings of isolation and fear. Shine exists to close this gap. We were the first charity in the UK to focus specifically on supporting young adults in their 20s, 30s, and 40s with cancer. We work alongside those with lived experience to create resources, programmes, and events that address their realities and help them feel less alone, more informed, and better equipped to face whatever challenges that cancer brings.

Vision

We want every adult in their 20s, 30s and 40s diagnosed with cancer to know they’re not alone, and to have the support, knowledge, and confidence to navigate whatever cancer throws their way.

Mission

There’s never a good time for a cancer diagnosis, but in your 20s, 30s or 40s there are particular challenges to navigate, like work, dating, finances and more. At Shine Cancer Support, we’ve been there and we get it. We’re here to help you deal with everything that your diagnosis brings, before, during and after treatment, and to welcome you into our community.

2024 - 2025 Impact

Main activities

Between 1 October 2024 and 31 December 2025, Shine continued to deliver a wide range of support activities for young adults with cancer across the UK. We focused on strengthening and expanding our programmes and events, further developing our volunteer-led networks, and continuing to refine the ways we measure and understand impact. We provided a mix of in-person and online offerings, recognising that both are needed to reach people across the country and to ensure the accessibility of events and programmes.

1. Online programmes

During the 2024-2025 period, we delivered our core online programmes: the Break Out programme for younger adults coming to the end of treatment or in remission, the Shine Circles programme for younger adults with incurable cancer, the Plus Ones Circle programme for the partners of younger adults with incurable cancer, and the Reset programme for adults aged 20 to 28.

These structured, six-week programmes provide facilitated, supportive spaces for participants to explore the impact of cancer on their lives, connect with others in similar situations, and consider new ways of supporting their emotional wellbeing. Each of the programme sessions ran for two hours over six weeks and were led by two trained facilitators; at least one facilitator in every pair had their own experience of cancer. The weekly sessions centre on topics like living with uncertainty, relationships, and processing emotions, and provide participants with a range of tools that they might find useful for coping with their experience.

SHINE CANCER SUPPORT

TRUSTEES' REPORT (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

In total, Shine delivered 15 online programmes to 157 young adults over the reporting period:

Programme Number of cohorts Number ofparticipants
Break Out- aimed at adults aged 20-49 in
treatment or in remission from cancer.
5		 55
Circles- aimed at younger adults with incurable
cancer
5		 51
Plus Ones- for the partners of those with an
incurable diagnosis
3		 31
Reset- for those aged 20-28 2 20
Total 15 157

Upon completing the programme, one Break Out participant wrote:

Signing up for the Break Out programme was one of the only good things to come out of my cancer journey. I was nervous about joining [...] but as soon as I joined that went away. The programme allowed me to say as little or as much as I wanted about each week’s topic and there was completely no judgement within the group.

One participant, who was part of a Circles group, wrote:

We really learned to empathise and listen to others, and it always felt like a safe space to share, even some of those more dark or personal thoughts that you might not want to share with family and friends. I really appreciated the format and themes of the sessions, and found the topics so relatable [...] It was so incredible to meet young people with incurable cancer who really get it.

We began to use a wellbeing valuation tool and the Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS) as a new framework for analysing our impact at the end of 2024. As a result, we have been able to gain an increasing amount of data on the impact of our online programmes and in-person events. This approach to social impact measurement evaluates change in individuals’ self-reported well-being and calculates the monetary equivalent of these impacts. We use SWEMWBS before and after key activities to understand how participants’ wellbeing changes over time, and to see whether the changes we observe are likely to be meaningful. Research suggests that a change of 3 points or more on the SWEMWBS represents a 'meaningful change' at an individual level.

Using this methodology, we found that our programmes bring about significant improvements in participant wellbeing. Using the SWEMWEBS framework, we found that across all programmes, each participant experienced an average change from baseline of 3.2, and an average wellbeing improvement equivalent to approximately £3,023.93 in social value, with wellbeing scores increasing by an average of 12.8%.

Participants on all programmes consistently identified peer connection as the most valuable element of the programme; this was cited by 74% of respondents as the best part of their experience. As of October 2025, we began to analyse participants’ responses to the UCLA Loneliness Scale, and found that, before programmes began in October, 62% of respondents often felt isolated from others. This number decreased to 36% after the programmes.

SHINE CANCER SUPPORT

TRUSTEES' REPORT (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

2. Shine Networks and Meet Ups

From October 2024 to the end of 2025, local Shine Networks facilitated 27 online meet-ups with a total of 189 attendees, and 170 in-person meet-ups with a total of 1,122 attendees across the UK.

The total number of online meet ups was reduced in 2025, as the online ‘Meet Ups for All’ were moved from a monthly to quarterly basis, as a result of decreased demand. Responding to this change, we began to focus these events on specific topics, an approach has yielded higher rates of attendance.

Year Type of meet up **Number of events ** Total number attending
Oct - Dec 2024 Online 6 38
Oct - Dec 2024 In-person 21 74
Jan - Dec 2025 Online 21 151
Jan - Dec 2025 In-person 149 1048

In-person Network meet-up attendees reported many positive responses to meet-ups. One recent attendee to a Manchester meet-up wrote:

Honestly, Shine has been life changing. I’ve met so many great people and already made a good few friends. I’ve travelled to Manchester to experience their amazing in-person meet-ups and I feel like a new person after only a few months!

Our in-person Network Leader Training Weekend, held in November 2025 allowed us to provide training and support to our volunteer Network leaders, who are scattered around the country. As a result of attending, participants reported feeling better supported and more equipped to lead their groups, and noted that they appreciated the combination of practical training, space for reflection, and time to connect with peers. One participant wrote:

I love the Network Leaders training weekend because it fills my cup, gives me energy to keep going. It also reminds me that I'm part of something bigger and amazing. And I like being a small part of something amazing.

In our 2025 Volunteer Survey, Network Leaders rated their satisfaction with their role with an average score of 8.8/10. In the same survey, respondents had an average of 9.3/10 when asked ‘how supported they felt as a Shine volunteer’.

3. Shine Shake Ups

We continued running our full-day in-person Shine Shake Up events, which launched in March 2024. These events bring together young adults with cancer for a day of workshops, peer connection, and support. We also introduced Shake Up Max, a residential weekend version of the Shake Up format, which saw strong interest and positive feedback. The success of these events demonstrates the ongoing need for intensive, in-person support opportunities.

SHINE CANCER SUPPORT

TRUSTEES' REPORT (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

From October 2024 through December 2025, 87 people attended a full-day Shake Up and gave the events an average rating of 4.7 stars out of 5.

Feedback included:

I felt so welcome and comfortable during the [Shake Up], even if I was nervous at first. It was a huge step for me to do this after so many years and I am already looking forward to the monthly socials and getting to know people more. I feel optimistic and less alone! Thank you for all you do. On a beautiful sunny day why would you want to sit inside all day with other cancer folks you've never met before, chatting about life with cancer? Well I'll be honest, immediately before this type of thing I didn't want to go! But good grief, it's good for me when I do! I laughed so much today and met fantastic people. Early onset cancer….can be really isolating, and being with a gang of others who get it, even though you've all had such different experiences or treatment, is amazing.

4. Social media

As of December 2025, Shine’s Facebook groups had 4,904 members. After conducting a focus group and a survey with a sample of Shine’s Facebook members, we made some improvements to the pages, making it easier for members to find the specific support they need.

Many participants described the group as a "comforting resource" that provided reassurance and a sense of normalcy during an abnormal time. The shared experiences and supportive comments helped members feel validated in their emotional responses to cancer.

Our social media presence has continued to grow, and by the end of 2025, we had 5,900 likes on Facebook and 6,249 followers on Instagram. At the start of 2026 we also began sharing more content on LinkedIn and will be measuring impact on this platform in the upcoming year.

5. Other resources

From October 2024 to December 2025, Shine produced 18 new podcasts on topics including sleep, family dynamics, palliative care, and anxiety. In 2025 alone, these podcasts were downloaded 5,817 times. Our Not Your Grandma’s Cancer Show series continues to be an important way of reaching younger adults with cancer, offering accessible, on-demand support and information, allowing people to engage with Shine content privately and at their own pace. Most episodes feature conversations with Shine community members, as well as experts from across the cancer and health space.

Reviews for Not Your Grandma’s Cancer Show have been overwhelmingly positive, with one listener writing:

This podcast is at once both highly engaging and a wonderful, deep well of resources to support cancer patients in the 18-50 age bracket, providing them with extremely insightful experience and tips and advice, and above all the emotional comfort of knowing they are not alone in facing this awful disease. Truly wonderful stuff.

SHINE CANCER SUPPORT

TRUSTEES' REPORT (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

Shine offers a range of booklets aimed at different groups within our service users demographics. This includes booklets on incurable cancer, being newly diagnosed with cancer, supporting yourself as a ‘plus one’ and living with chronic cancer. These booklets are a useful way for healthcare professionals to introduce Shine and our services to their patients, and across 2024 and 2025 we have continued to distribute our booklets and finalised a booklet on ‘cancer in your 20s’. We have also updated our Shine Services booklet to reflect all of our current offerings.

We launched a new website in February 2025, representing a significant milestone in our infrastructure development. The new site features improved navigation, enhanced accessibility features, better integration of our resources, and an upgraded donation function that makes it easier for supporters to contribute to our work. Early feedback on the new website has been positive, with users noting that programmes and resources are now easier to find. In total, the website received more than 237,000 hits to the main page across the reporting period.

We also have made progress on upgrading our use of Salesforce, our CRM system. While this project is ongoing, we now have improved functionality to use it for tracking fundraisers and donors, as well as ensuring that regular newsletters are sent to different stakeholders including donors/fundraisers, service users, and healthcare professionals. We are continuing to upgrade the system with the aim of using it more effectively to manage our programmes and programme participants.

6. Shine Connect

Our 2024 Shine Connect conference was held in-person on 12 October 2024 at Wallacespace Clerkenwell, with 120 attendees. On Sunday 13 October, we ran a number of online workshops.

In total, we offered 13 sessions on 12th October which covered:

In addition, we had counsellors available for one-to-one sessions and therapy dogs available at lunch.

On the 13th of October, 2024, we ran four sessions, namely: Communicating with your partner, Finding your feet when returning to work, Managing menopause, and Understanding your changing identity after cancer.

SHINE CANCER SUPPORT

TRUSTEES' REPORT (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

We received overwhelmingly positive feedback on the event. Respondents gave the event an average of 4.8* out of 5, with similar scores for the food and the venue.

Thank you SO much for holding this conference. I was so lonely before I found Shine, and for the first time I feel hopeful that there won't be "nothing" - I have an opportunity to connect with people like me, and that gives me hope xx

It was such a brilliant day. Thank you so much for organising it. I can’t wait for the next one!

Thank you for this event, I know a huge amount if work must go into organisation today. I thought sessions were really well facilitated, and I thought it was an incredibly welcoming and inclusive event.

After the 2024 conference, we established a Shine Connect Steering Committee to ensure that Shine Connect continues to meet the needs and interests of the Shine community.

Our 2025 Shine Connect conference sold out very quickly, with little promotion required. The conference, which ran on 11th October in Wallacespace Clerkenwell, had 130 attendees.

This conference brought together younger adults from all across the UK, providing a full day of support, connection, and opportunities to learn. The conference featured an introductory session, a keynote speaker section (featuring Dr. Kairbaan Hodivala-Dilke, the Deputy Institute Director at Barts Cancer Institute), therapy dogs, and one-to-one support offerings, in addition to offering attendees the chance to attend two workshops of their choice (of 12 options) during the afternoon.

Shine Connect attendees gave the event an average rating of 4.75 stars out of 5. A few responses from Shine Connect attendees after the event included:

I had an absolutely fantastic time at the conference, which was delivered perfectly. I’ve also made friends for life through Shine.

Thank you for organising such an enjoyable, positive event. I loved the venue, food and format for the day.

It exceeded every expectation and I can’t wait to attend next year!

We will be hosting the 2026 conference in a larger venue to accommodate more attendees. Because of the success of the 2025 Shine Connect Steering Committee, we have recruited a new group of 12 younger adults with cancer to be part of the 2026 Steering Committee, who have already started helping us to shape our upcoming Shine Connect.

7. Shine Camp

Shine Camp accommodated 104 participants in 2025 and ran from 25-28 July, 2025 in Dorset. This annual event brought together younger adults with cancer and their families, including partners, children, and pets, for a weekend of connection. We introduced facilitated group sessions to Shine Camp, meaning that the weekend now offers not only social connection but also a designated space for processing and sharing experiences in a more structured way. This addition was well-received by attendees.

Shine Camp received an average rating of 4.8/5 stars, and 100% of survey respondents said that they would like to return to Shine Camp the following year.

SHINE CANCER SUPPORT

TRUSTEES' REPORT (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

After Shine Camp, feedback from attendees included:

Shine Camp is better than I can explain - everyone bonds quickly and is welcoming to everyone. There is a mix of time to chat about shared experiences and time to forget about it and being silly, lots of laughs and some cathartic tears, so I always leave feeling like my soul has been refreshed and full of so much love and hope.

It felt like a big leap of faith for us to attend the first time we did (as we'd not previously been involved in Shine) but now we genuinely plan our whole summer around it.

Shine Camp is more than just a place to stay for a few days; it's a community where you can truly be yourself. You'll get to meet new people from all different backgrounds and forge friendships that can last a lifetime. Shine staff and volunteers are there to help you, making sure you feel welcome.

8. Workshops for healthcare professionals (HCPs)

From October 2024 to December 2025, we continued to provide CPD-accredited training to healthcare professionals across the UK on the needs of younger adults with cancer. We delivered six workshops to 97 people across the country.

Of those attending, 69% reported that they felt “a lot” better able to support their patients as a result of attending. 100% reported that they would recommend the workshop to a colleague.

Feedback received included:

I wish I had known of your services and support sooner. I wasn't really aware of what you offered and how valuable this can be to younger adults with cancer. I wish I had known to ask all of the patients in their 20s, 30s and 40s about their relationships and fertility worries, what a shame this wasn't taught in my nurse training to focus more on some psychological support - however, I can start now!

In March 2025, we launched a new CPD-accredited Shine Champions programme, which provided training to 20 healthcare professionals across the country. This first cohort gained knowledge about the issues of younger adults with cancer, information on relevant research, and an understanding about how to better work with this community in a way that centres the needs of this patient population. Shine Champions met twice for full-day, inperson training sessions with the Shine team and other experts in the field, attended ‘lunch and learn’ sessions on important topics, and networked with others in similar job roles. Through the programme, Shine also directed Champions toward tools and resources for speaking with colleagues and other professionals about how they can best support younger adults with cancer. This programme will be full evaluated after it ends in February 2026, however, because of its success to-date, the size of our 2026 Shine Champions cohort has doubled. We’re looking forward to continuing to grow this programme in future years.

SHINE CANCER SUPPORT

TRUSTEES' REPORT (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

9. Advocacy and involvement

From autumn 2024 through winter 2025, Shine’s influencing and advocacy activities have grown. We have not only taken part in more national and local campaigns and activities, but also conducted our own research into the current needs of younger adults with cancer. We were also recognised as an important part of the cancer support landscape in May 2025, when we received an invitation to Buckingham Palace for members of the ‘cancer support community’. In addition:

In addition, we have undertaken two important pieces of research which will be published in 2026. The Shine Cancer Experience Survey was run by Branding Science at the end of 2024 and into 2025. We have also been working with ZS, a consultancy company, to do a small piece of work on the financial impact of cancer. Five qualitative interviews were carried out and analysed by the ZS team. We have since collaborated to form a set of recommendations from this research. This report will be launched in April 2026 and, along with our other survey, will form the basis of future advocacy and influencing activities.

Financial review

At the end of the period the charity had unrestricted funds of £457,622 (2024: £409,019) and restricted funds of £179,565 (2024: £92,081). The charity's free reserves (unrestricted funds less long-term assets) are £323,921 (2024: £290,309).

Reserves policy

In the Trustees' view, the reserves should provide the charity with adequate financial stability and the means for it to meet its charitable objectives for the foreseeable future. At a time of growth within the charity, the accounts are monitored monthly by the Co-CEOs and discussed quarterly with the Trustees to allow analysis of unexpected events, risks and issues to be managed.

SHINE CANCER SUPPORT

TRUSTEES' REPORT (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

Our policy is to maintain a level of reserves equal to 80% of 9 months budget (for 2025/26 this equals £374k) in order to provide stability across the organisation. This enables us to provide staff with security in their jobs, as well as ensuring that we are able to continue to provide a basic level of support to all of our service users in the event of a major financial downturn or event that impacts our income or ability to provide services as planned. (e.g. another pandemic).

At the end of this financial period (31/12/25) we hold £50k free reserves below the current target.

Plans for future periods

Demand for Shine services continues to grow and our strategic plans include expansion of our services and overall growth of the charity. The Trustees believe this approach will allow us to provide support and continuity to the growing community of young adults with cancer in an uncertain financial context.

Structure, governance and management

Shine Cancer Support was formed by Constitution, which was agreed on 23rd September 2009. The association was registered as a charity with the Charities Commission of England & Wales on 17th April 2012 with the three founding Trustees: Emma Willis, Ceinwen Giles, and Laura Purandare.

The Trustees oversee the charity and, by the end of this financial year, there were ten people employed by the charity. No Trustees are paid for carrying out their official duties.

Other professionals have been paid for providing specific services to the charity on an invoice basis that does not constitute employment. The Trustees make decisions regarding the running and management of the charity with day-to day management delegated to the two Co-CEOs who are supported by the staff and volunteers who carry out specific tasks and roles that do not involve major decision-making.

The trustees who served during the period and up to the date of signature of the financial statements were: C Riley

R J Cranefield

R Salter

L Purandare

J Talman

F A Woodcock

Recruitment and appointment of trustees

Recruitment and appointment of new Trustees is the responsibility of the existing Trustees.

The Trustees may appoint any person who is willing to act as Trustee subject to the requirements of the Charity Commission and the Constitution.

The Trustees have had due regard to the commission’s public benefit guidance when exercising any powers or duties to which the guidance is relevant. The Trustees have given consideration to the major risks to which the charity is exposed and satisfied themselves that systems or procedures are established in order to manage those risks. There were no serious incidents to report during the financial year.

SHINE CANCER SUPPORT

TRUSTEES' REPORT (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

The trustees' report was approved by the Board of Trustees.

.............................. C Riley Trustee 19.6.26 Date: .............................................

SHINE CANCER SUPPORT

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF SHINE CANCER SUPPORT

I report to the trustees on my examination of the financial statements of Shine Cancer Support (the charity) for the period ended 31 December 2025.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity’s financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

I M Rodd BSc FCA FCCA TC Group Waverley House 115-119 Holdenhurst Road Bournemouth Dorset BH8 8DY

Dated: .........................24 June 2026

SHINE CANCER SUPPORT

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE PERIOD ENDED 31 DECEMBER 2025

Unrestricted
Restricted
funds
funds
2025
2025
Notes
£
£
Income from:
Donations and legacies
3
297,696
442,104
Charitable activities
4
6,542
-
Other trading activities
5
4,982
-
Investments
6
12,145
-
Total income
321,365
442,104
Expenditure on:
Raising funds
7
23,522
-
Charitable activities
243,963
375,096
Total expenditure
267,485
375,096
Net gains/(losses) on
investments
12
15,199
-
Net income
69,079
67,008
Transfers between
funds
(20,476)
20,476
Net movement in
funds
9
48,603
87,484
Reconciliation of funds:
Fund balances at 1 October
2024
409,019
92,081
Fund balances at 31 December
2025
457,622
179,565		 Total
Unrestricted
Restricted
funds
funds
2025
2024
2024
£
£
£
739,800
175,480
174,599
6,542
3,076
-
4,982
6,580
-
12,145
8,416
-
763,469
193,552
174,599
23,522
13,304
-
619,059
179,647
178,512
642,581
192,951
178,512
15,199
15,164
-
136,087
15,765
(3,913)
-
(21)
21
136,087
15,744
(3,892)
501,100
393,275
95,973
637,187
409,019
92,081		 Total
2024
£
350,079
3,076
6,580
8,416
368,151
13,304
358,159
371,463
15,164
11,852
-
11,852
489,248
501,100

The statement of financial activities includes all gains and losses recognised in the period. All income and expenditure derive from continuing activities.

SHINE CANCER SUPPORT

STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2025

2025
Notes
£
Fixed assets
Property, plant and equipment
14
Investments
15
Current assets
Trade and other receivables
16
11,294
Cash at bank and in hand
499,833
511,127
Current liabilities
17
(7,641)
Net current assets
Total assets less current liabilities
The funds of the charity
Restricted income funds
19
Unrestricted funds
20
The financial statements were approved by the trustees on .........................
..............................
..............................
C Riley
R Salter
Trustee
Trustee
19.6.26		 £
2,640
131,061
133,701
503,486
637,187
179,565
457,622
637,187		 2024
£
13,573
379,657
393,230
(10,840)		 £
2,848
115,862
118,710
382,390
501,100
92,081
409,019
501,100

SHINE CANCER SUPPORT

STATEMENT OF CASH FLOWS

FOR THE PERIOD ENDED 31 DECEMBER 2025

Notes
Cash flows from operating activities
Cash generated from/(absorbed by)
operations
23
Investing activities
Purchase of property, plant and equipment
Investment income received
Net cash generated from investing activities
Net cash used in financing activities
Net increase/(decrease) in cash and cash
equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period		 2025
£
(3,598)
12,145		 £
111,629
8,547
-
120,176
379,657
499,833		 2024
£
(1,006)
8,416		 £
(26,058)
7,410
-
(18,648)
398,305
379,657

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 DECEMBER 2025

1 Accounting policies

Charity information

Shine Cancer Support is a charitable unincorporated association. Registered at the Charity Commission.

1.1 Reporting period

These financial statements cover an extended 15 month period from 1 October 2024 to 31 December 2025. As a result of this change, comparative figures are not entirely comparable.

1.2 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Charities Act 2011, FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.4 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.5 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

1 Accounting policies

(Continued)

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Government Grants

Government grants shall be recognised in profit or loss on a systematic basis over the periods in which the entity recognises as expenses the related costs for which the grants are intended to compensate.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset’s use.

1.7 Property, plant and equipment

Property, plant and equipment are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings Straight line over 3 years Computers Straight line over 3 years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

1 Accounting policies

(Continued)

1.8 Non-current investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.9 Impairment of non-current assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.10 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.11 Financial instruments

The charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other receivables and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including trade and other payables and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

1 Accounting policies

(Continued)

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity’s contractual obligations expire or are discharged or cancelled.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity’s accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

Unrestricted
Restricted
funds
funds
2025
2025
£
£
Donations and gifts
108,983
-
Grants
-
442,104
Sponsorship
170,168
-
Other
18,545
-
297,696
442,104		 Total
Unrestricted
Restricted
funds
funds
2025
2024
2024
£
£
£
108,983
21,960
-
442,104
5,000
174,599
170,168
97,936
-
18,545
50,584
-
739,800
175,480
174,599		 Total
2024
£
21,960
179,599
97,936
50,584
350,079

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

3
Income from donations and legacies
Unrestricted
Restricted
funds
funds
2025
2025
£
£
Grants
The National Lottery
-
145,222
Oak Foundation
-
240,000
Merck
-
7,968
Point of Care Foundation
-
18,414
St James' Place
-
10,000
Cabaret V Cancer
-
9,000
Glaxo Smith Kline UK
-
6,500
BBK
-
5,000
-
442,104
4
Income from charitable activities
Charitable activities
Conference
5
Income from other trading activities
Fundraising events
Shop income
Other income
Other trading activities		 Total
Unrestricted
Restricted
Total
funds
funds
2025
2024
2024
2024
£
£
£
£
(Continued)
145,222
-
136,946
136,946
240,000
-
20,260
20,260
7,968
-
6,879
6,879
18,414
-
5,000
5,000
10,000
5,000
-
5,000
9,000
-
3,000
3,000
6,500
-
1,611
1,611
5,000
-
903
903
442,104
5,000
174,599
179,599
Unrestricted
Unrestricted
funds
funds
2025
2024
£
£
6,542
3,076
Unrestricted
Unrestricted
funds
funds
2025
2024
£
£
1,075
285
307
520
3,600
5,775
4,982
6,580		 Total
Unrestricted
Restricted
Total
funds
funds
2025
2024
2024
2024
£
£
£
£
(Continued)
145,222
-
136,946
136,946
240,000
-
20,260
20,260
7,968
-
6,879
6,879
18,414
-
5,000
5,000
10,000
5,000
-
5,000
9,000
-
3,000
3,000
6,500
-
1,611
1,611
5,000
-
903
903
442,104
5,000
174,599
179,599
Unrestricted
Unrestricted
funds
funds
2025
2024
£
£
6,542
3,076
Unrestricted
Unrestricted
funds
funds
2025
2024
£
£
1,075
285
307
520
3,600
5,775
4,982
6,580
6,580

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

6 Income from investments

Unrestricted Unrestricted
funds funds
2025 2024
£ £
Interest receivable 12,145 8,416
7 Expenditure on raising funds
Unrestricted Unrestricted
funds funds
2025 2024
£ £
Fundraising and publicity
Fundraising fees 23,522 13,304
8 Support costs allocated to activities
2025 2024
£ £
Insurance 2,316 1,331
Governance costs 6,479 9,233
8,795 10,564
Analysed between:
Unrestricted Funds 8,795 10,564
2025 2024
Governance costs comprise: £ £
Audit and IE fees 3,600 7,332
Accountancy 2,485 1,524
Bank fees 347 377
Trustee expenses 47 -
6,479 9,233

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

9 Net movement in funds 2025 2024
£ £
The net movement in funds is stated after charging/(crediting):
Fees payable for the independent examination of the charity's financial
statements 3,600 -
Fees payable for the audit of the charity's financial statement - 7,332
Depreciation of owned property, plant and equipment 3,806 2,830

10 Trustees

There were no trustees' remuneration or other benefits for the period ended 31 December 2025 nor for the year ended 30 September 2024.

Trustees are remunerated in accordance with the Charities constitution for work that falls outside of their Trustee duties.

Trustees' expenses

During the period ended 31 December 2025, 2 trustees (2024: none) received reimbursement for travel expenses totalling £47 (2024: £nil).

11 Employees

The average monthly number of employees during the period was:

Head count
Employment costs
Wages and salaries
Social security costs
Other pension costs		 2025
Number
9
2025
£
358,383
31,438
7,594
397,415		 2024
Number
8
2024
£
228,670
16,933
4,895
250,498

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

11 Employees (Continued)
The number of employees whose annual remuneration was more than
£60,000 is as follows:
2025 2024
Number Number
£60,000 - £70,000 2 -
Remuneration of key management personnel
The remuneration of key management personnel was as follows:
2025 2024
£ £
Aggregate compensation 157,669 118,666
12 Gains and losses on investments
Unrestricted Unrestricted
funds funds
2025 2024
Gains/(losses) arising on: £ £
Revaluation of investments 15,199 15,164

13 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

14
Property, plant and equipment
Fixtures and
fittings
£
Cost
At 1 October 2024
-
Additions
1,490
At 31 December 2025
1,490
Depreciation and impairment
At 1 October 2024
-
Depreciation charged in the period
331
At 31 December 2025
331
Carrying amount
At 31 December 2025
1,159
At 30 September 2024
-
15
Fixed asset investments
Cost or valuation
At 1 October 2024
Valuation changes
At 31 December 2025
Carrying amount
At 31 December 2025
At 30 September 2024
There were no investment assets outside the UK.		 Computers
Total
£
£
9,766
9,766
2,108
3,598
11,874
13,364
6,918
6,918
3,475
3,806
10,393
10,724
1,481
2,640
2,848
2,848
Unlisted
investments
£
115,862
15,199
131,061
131,061
115,862		 Total
£
9,766
3,598
13,364
6,918
3,806
10,724
2,640
2,848
131,061
131,061
115,862

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

16
Trade and other receivables
Amounts falling due within one year:
Trade receivables
Prepayments and accrued income
17
Current liabilities
Trade payables
Other payables
Accruals and deferred income
18
Retirement benefit schemes
Defined contribution schemes
Charge to profit or loss in respect of defined contribution schemes		 2025
£
2,022
9,272
11,294
2025
£
2,337
1,704
3,600
7,641
2025
£
7,594		 2024
£
5,000
8,573
13,573
2024
£
1,299
1,609
7,932
10,840
2024
£
4,895

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

19 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

At 1
Lottery funding
Oak Foundation
Winston Churchill 2
Gilead
Pfizer Limited
Merck/MSD
Cabaret vs Cancer
The Access Foundation
Astellas Pharma Ltd
BBK
Glaxo Smith Kline UK
St James' Place
Point of Care Foundation
VBG Camp
Previous year:
At 1
Lottery funding
Oak foundation
Merck/MSD
Winston Churchill 2
Gilead
Pfizer Limited
Cabaret Vs Cancer
The Access Foundation
Astellas Pharma Ltd
VBG Camp		 October
2024
Incoming
resources
Resources
expended
Transfers
At 31
December
2025
£
£
£
£
£
50,879
145,222
(173,642)
18,856
41,315
-
240,000
(150,000)
-
90,000
3,814
-
(3,827)
13
-
6,258
-
(6,258)
-
-
13,146
-
(13,879)
733
-
4,186
7,968
(4,186)
-
7,968
3,000
9,000
(5,000)
-
7,000
5,000
-
(5,000)
-
-
1,293
-
(1,831)
538
-
-
5,000
(2,134)
-
2,866
-
6,500
(6,836)
336
-
-
10,000
(2,503)
-
7,497
-
18,414
-
-
18,414
4,505
-
-
-
4,505
92,081
442,104
(375,096)
20,476
179,565
October
2023
Incoming
resources
Resources
expended
Transfers
At 30
September
2024
£
£
£
£
£
-
136,946
(86,067)
-
50,879
64,617
-
(64,638)
21
-
-
6,879
(2,693)
-
4,186
9,530
-
(5,716)
-
3,814
17,321
903
(11,966)
-
6,258
-
20,260
(7,114)
-
13,146
-
3,000
-
-
3,000
-
5,000
-
-
5,000
-
1,611
(318)
-
1,293
4,505
-
-
-
4,505
95,973
174,599
178,512
21
92,081		 October
2024
Incoming
resources
Resources
expended
Transfers
At 31
December
2025
£
£
£
£
£
50,879
145,222
(173,642)
18,856
41,315
-
240,000
(150,000)
-
90,000
3,814
-
(3,827)
13
-
6,258
-
(6,258)
-
-
13,146
-
(13,879)
733
-
4,186
7,968
(4,186)
-
7,968
3,000
9,000
(5,000)
-
7,000
5,000
-
(5,000)
-
-
1,293
-
(1,831)
538
-
-
5,000
(2,134)
-
2,866
-
6,500
(6,836)
336
-
-
10,000
(2,503)
-
7,497
-
18,414
-
-
18,414
4,505
-
-
-
4,505
92,081
442,104
(375,096)
20,476
179,565
October
2023
Incoming
resources
Resources
expended
Transfers
At 30
September
2024
£
£
£
£
£
-
136,946
(86,067)
-
50,879
64,617
-
(64,638)
21
-
-
6,879
(2,693)
-
4,186
9,530
-
(5,716)
-
3,814
17,321
903
(11,966)
-
6,258
-
20,260
(7,114)
-
13,146
-
3,000
-
-
3,000
-
5,000
-
-
5,000
-
1,611
(318)
-
1,293
4,505
-
-
-
4,505
95,973
174,599
178,512
21
92,081
92,081

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

19 Restricted funds

(Continued)

Funds are restricted for the following purposes:

VBG Camp - This is income to be spent specifically on the camp run by Shine on an annual basis.

Lottery - To build and strengthen the community of young adults with cancer, reducing isolation and improving mental well-being.

Oak Foundation - Core support to improve the lives of young adults with cancer through the strengthening and development of Shine’s structure, programmes and resources.

Winston Churchill MT 2 - To support the creation of a programme to support people transitioning from teenage cancer services.

Gilead - To support a programme of events and resource creation to tackle inequalities.

Pfizer Limited - To support Shine Shake Up Programme 2024-2025.

Merck/MSD - To support a programme of events and resource creation to tackle inequalities.

Cabaret Vs Cancer - To support Shine Shake Up Programme.

The Access Foundation - To support Shine Reset Programme and Part-Funding for Shine Shake-Up Programme.

Astellas Pharma Ltd - To support HCP workshops from August 2024 - March 2025.

BBK - To support two Shine Shake Up days taking place in London.

Glaxo Smith Kline UK - To support the building of a trained cohort of Shine Champions.

Point of Care Foundation - To support the training of 220 Health Care Professionals, giving them the skills to improve and humanise care for young adults with cancer in their 20s, 30s and 40s.

St James Place - TO provide four all day 'Shake Up' events to support 100 young people in their 20s, 30s and 40s with cancer.

Transfers between funds:

Transfers have taken place between the General fund and restricted funds to cover an overspend on the restricted funds.

A transfer has taken place between the Lottery fund and the General fund to correct the prior year allocation of lottery expenditure.

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

20 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

At 1 October
Incoming		 Resources Transfers Gains and At 31
2024 resources expended losses December
2025
£ £ £ £ £ £
General funds 409,019 321,365 (267,485) (20,476) 15,199 457,622
Previous year: At 1 October
Incoming		 Resources Transfers Gains and At 30
2023 resources expended losses September
2024
£ £ £ £ £ £
General funds 393,275 193,552 (192,951) (21) 15,164 409,019
Analysis of net assets between funds
Unrestricted Restricted Total
funds funds
2025 2025 2025
£ £ £
At 31 December 2025:
Property, plant and equipment 2,640 - 2,640
Investments 131,061 - 131,061
Current assets/(liabilities) 323,921 179,565 503,486
457,622 179,565 637,187
Unrestricted Restricted Total
funds funds
2024 2024 2024
£ £ £
At 30 September 2024:
Property, plant and equipment 2,848 - 2,848
Investments 115,862 - 115,862
Current assets/(liabilities) 290,309 92,081 382,390
409,019 92,081 501,100

21 Analysis of net assets between funds

SHINE CANCER SUPPORT

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE PERIOD ENDED 31 DECEMBER 2025

22 Related party transactions

Transactions with related parties

During the period ended 31 December 2025, no trustees (2024: one) were paid a total of £nil (2024: £777) for freelance services.

During the period ended 31 December 2025, one trustee's spouse (2024: nil) was paid a total of £40 (2024: £nil) for freelance services.

During the period ended 31 December 2025, one trustee (2024: nil) received a gift hamper totalling £24 (2024: £nil) for speaking at a Network leaders weekend.

23
Cash generated from operations
Surplus for the period
Adjustments for:
Investment income recognised in statement of financial activities
Gain on disposal of investments
Depreciation and impairment of property, plant and equipment
Movements in working capital:
Decrease/(increase) in trade and other receivables
(Decrease) in trade and other payables
Cash generated from/(absorbed by) operations		 2025
£
136,087
(12,145)
(15,199)
3,806
2,279
(3,199)
111,629		 2024
£
11,852
(8,416)
(15,164)
2,830
(11,571)
(5,589)
(26,058)

24 Analysis of changes in net funds

The charity had no material debt during the year.